Ask about this productRelated genes to: FLT3LG antibody
- Gene:
- FLT3LG NIH gene
- Name:
- fms related tyrosine kinase 3 ligand
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-21
- Date modifiied:
- 2016-10-24
Related products to: FLT3LG antibody
Related articles to: FLT3LG antibody
- Uveal melanoma (UM) lacks minimally invasive and reproducible biomarkers to support clinical risk stratification, motivating the need for molecular profiling of aqueous humor (AH) as an alternative to fine-needle tumor aspiration (FNAB). This study aimed to generate a calibrated AH protein concentration map to identify tumor-associated signals present at clinically measurable levels and assess their associations with established molecular and clinical features. AH samples from 70 UM eyes were analyzed using next-generation sequencing-based proximity extension assays (PEAs), and leftover AH from 27 samples was further assessed using qPCR-based PEA to obtain reference concentration values. Regression models derived from overlapping proteins enabled extrapolation of calibrated pg/mL-level concentrations across the full cohort. Twenty-three proteins had median modeled concentrations above 5 pg/mL and were examined for clinical relevance and translational feasibility. Several proteins, including CXCL8, CXCL10, VEGFA, HGF, PDCD1, FLT1, FLT3LG, and CCL2, showed progressive increases from GEP1/PRAME- to GEP2/PRAME+ tumors and from AJCC Stage I/II to Stage III/IV, with Stage IV tumors demonstrating significant elevations in CXCL8, VEGFA, and PDCD1. Pathway analysis revealed activation of inflammatory and tumor microenvironment pathways, and upstream regulator analysis identified VEGFA and CCL2 as potential drivers. These findings demonstrate that calibrated AH proteomic profiling can identify clinically measurable protein changes associated with UM risk and stage, supporting its potential utility for biomarker development. - Source: PubMed
Publication date: 2026/03/30
Huang ElaineChen YilinPeng Chen-ChingLiang DonnyReid MarkKhoche AtreyKuhn PeterMason JeremyJiang XuejuanBerry Jesse LXu Liya - A blood-based test capable of predicting progression to active tuberculosis (TB) before symptom onset could reduce numbers needed to treat and mitigate disease transmission. This study evaluated plasma protein as predictors of TB progression within a cohort of close contacts from a university TB outbreak. Plasma from 17 progressors who developed TB within 2 years, 28 interferon-gamma release assay (IGRA)-positive non-progressors, and 33 IGRA-negative healthy controls was profiled using the Olink proteomics platform. Progressors showed broad downregulation of proteins related to immune regulation, cell adhesion, and nucleotide metabolism, while no significant differences were observed between non-progressors and healthy controls. A six-protein panel comprising LRP11, REG4, FLT3LG, CCDC80, ADA, and DPP7 discriminated progressors from others with AUCs exceeding 0.85. Transcriptomic validation in two independent cohorts support consistent downregulation of these markers. These findings highlight a distinct protein signature with potential for risk differentiation of TB progression and inform the development of targeted preventive strategies. - Source: PubMed
Publication date: 2026/02/20
Han YutongShao YanLiu QiaoZhu LimeiChen ChengXu Biao - Western diets, rich in refined fats and carbohydrates, are recognized as a major player in hepatic lipid accumulation in adults and youngsters, leading to the growing prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease, the gate to cirrhosis and cancer. Due to the lack of approved therapies, antioxidant-rich dietary regimens targeting MASLD relevant pathologic pathways may be of more immediate translational impact. As tomatoes are a major globally accessible source of antioxidant/inflammatory nutrients, we have investigated whether a novel whole tomato-based food supplement (WTFS), possessing an effective antioxidant activity and hindering multiple metabolic pathways, can interfere with mechanisms fostering MASLD progression. - Source: PubMed
Publication date: 2026/02/27
Natali Pier GiorgioImberti LuisaPiantelli MauroMinacori MarcoSottini AlessandraGianazza EricaBanfi Cristina - Serrated adenocarcinoma (SAC) represents a molecularly heterogeneous subtype of colorectal carcinoma (CRC) linked to the serrated pathway. It is aimed to clarify the molecular mechanisms underlying SAC development. Digital slides from The Cancer Genome Atlas (TCGA) colorectal adenocarcinoma Firehose Legacy dataset (632 cases) were reviewed, and cases were classified as SAC, partial-SAC, or classical CRC. Genomic alterations, mRNA expression, and DNA hypermethylation were compared using cBioPortal. Enrichment analyses were performed via WebGestalt, and protein-protein interaction (PPI) networks with hub genes were identified using STRING and Cytoscape. Statistical significance was defined as < 0.05 and < 0.05. The results revealed that the groups showed significant differences in the expression of 327 genomic alterations, 20 mRNAs, and 21 methylated genes ( < 0.0001, < 0.0001). Hub genes were , , , , , , , , , and . The pathways associated with differently expressed genes were the following: cell structure and morphology (phagocytic vesicle, microvillus, endocytosis, and immobile cilium), protein kinase activity (particularly MAPK), and immunological mechanisms. The hub genes act as molecular bridges connecting the observed genomic and epigenetic variations, particularly driving chromatin-related regulation and MAPK signaling pathways. In particular, , , , , and genes offer promising molecular targets for future therapeutic approaches in SACs. - Source: PubMed
Publication date: 2026/02/04
Sagnak Yilmaz ZeynepDemir Kececi SibelSagol OzgulSarioglu Sulen - Immune checkpoint blockade (ICB) therapy has transformed the treatment landscape for metastatic melanoma, yet predicting therapeutic response remains a significant challenge. This study hypothesizes that coordinated ligand-receptor (LR) interactions within the tumor microenvironment (TME) critically influence ICB efficacy and proposes that a novel LR pair-based signature score (LRPS) derived from on-treatment samples can predict clinical outcomes. In this study, we analyzed publicly available transcriptomic and clinical datasets comprising 144 patients and 168 on-treatment tumor samples from five independent cohorts (GEO: GSE120575, GSE115821, GSE168204; BioProject: PRJEB23709; dbGaP: phs001919.v1.p1; EGA: EGAD00001005738). We identified seven LR pairs (FLT3-FLT3LG, LY9-LY9, CD5-CD5, CD40LG-ITGA2B/ITGB3, APP-CD74, TNFRSF17-TNFSF13, FCER2-ITGAV/ITGB3) significantly associated with treatment outcomes. LRPS demonstrated strong predictive power, achieving an area under the ROC curve (AUC) exceeding 0.80 in four independent cohorts. Patients in the high-LRPS group exhibited higher ICB response rates (up to 76.2%) and significantly better progression-free survival (PFS) and overall survival (OS) compared with the low-LRPS group. In conclusion, we identified and verified an LRPS signature that provides a theoretical basis for applying such signatures derived from on-treatment tumor samples to predict therapeutic responses to ICB therapies. - Source: PubMed
Publication date: 2026/01/09
Zeng HuanchengZhang RendongJiang QiongzhiWu JundongZhuang ZheminFang Yutong